Remarks

New Claims 23 to 47 have support throughout the Specification. For example, enhancing glucose control by lowering glucose levels in hyperglycemic patients in discussed on page 8, lines 12 through 28. Insulin secretion and insulinotropic activity are discussed on page 9 and page 14, lines 9 through 11. The benefits of combined therapy on HbA1c levels are disclosed in Table 1 on page 19.

Respectfully submitted,

Mark J. Stewart

Attorney for Applicants Registration No. 43,936

Phone: 317-276-0280

Eli Lilly and Company Patent Division/MJS P.O. Box 6288 Indianapolis, Indiana 46206-6288

October 6, 2003